Literature DB >> 19647749

The folding pathway of the antibody V(L) domain.

Emma Rhiannon Simpson1, Eva Maria Herold, Johannes Buchner.   

Abstract

Antibodies are modular proteins consisting of domains that exhibit a beta-sandwich structure, the so-called immunoglobulin fold. Despite structural similarity, differences in folding and stability exist between different domains. In particular, the variable domain of the light chain V(L) is unusual as it is associated with misfolding diseases, including the pathologic assembly of the protein into fibrillar structures. Here, we have analysed the folding pathway of a V(L) domain with a view to determine features that may influence the relationship between productive folding and fibril formation. The V(L) domain from MAK33 (murine monoclonal antibody of the subtype kappa/IgG1) has not previously been associated with fibrillisation but is shown here to be capable of forming fibrils. The folding pathway of this V(L) domain is complex, involving two intermediates in different pathways. An obligatory early molten globule-like intermediate with secondary structure but only loose tertiary interactions is inferred. The native state can then be formed directly from this intermediate in a phase that can be accelerated by the addition of prolyl isomerases. However, an alternative pathway involving a second, more native-like intermediate is also significantly populated. Thus, the protein can reach the native state via two distinct folding pathways. Comparisons to the folding pathways of other antibody domains reveal similarities in the folding pathways; however, in detail, the folding of the V(L) domain is striking, with two intermediates populated on different branches of the folding pathway, one of which could provide an entry point for molecules diverted into the amyloid pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647749     DOI: 10.1016/j.jmb.2009.07.075

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  10 in total

1.  A residue-specific shift in stability and amyloidogenicity of antibody variable domains.

Authors:  Cardine N Nokwe; Martin Zacharias; Hisashi Yagi; Manuel Hora; Bernd Reif; Yuji Goto; Johannes Buchner
Journal:  J Biol Chem       Date:  2014-08-05       Impact factor: 5.157

Review 2.  How antibodies fold.

Authors:  Matthias J Feige; Linda M Hendershot; Johannes Buchner
Journal:  Trends Biochem Sci       Date:  2009-12-21       Impact factor: 13.807

3.  Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations.

Authors:  Luis M Blancas-Mejía; Alexander Tischer; James R Thompson; Jonathan Tai; Lin Wang; Matthew Auton; Marina Ramirez-Alvarado
Journal:  J Mol Biol       Date:  2013-10-22       Impact factor: 5.469

4.  Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.

Authors:  Pamina Kazman; Marie-Theres Vielberg; María Daniela Pulido Cendales; Lioba Hunziger; Benedikt Weber; Ute Hegenbart; Martin Zacharias; Rolf Köhler; Stefan Schönland; Michael Groll; Johannes Buchner
Journal:  Elife       Date:  2020-03-10       Impact factor: 8.140

5.  A single residue switch reveals principles of antibody domain integrity.

Authors:  Benedikt Weber; Matthias J Brandl; María Daniela Pulido Cendales; Carolin Berner; Tejaswini Pradhan; Gina Maria Feind; Martin Zacharias; Bernd Reif; Johannes Buchner
Journal:  J Biol Chem       Date:  2018-09-18       Impact factor: 5.157

Review 6.  What lessons can be learned from studying the folding of homologous proteins?

Authors:  Adrian A Nickson; Jane Clarke
Journal:  Methods       Date:  2010-06-04       Impact factor: 3.608

7.  MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors.

Authors:  Manuel Hora; Riddhiman Sarkar; Vanessa Morris; Kai Xue; Elke Prade; Emma Harding; Johannes Buchner; Bernd Reif
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

8.  Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.

Authors:  Manuel Hora; Martin Carballo-Pacheco; Benedikt Weber; Vanessa K Morris; Antje Wittkopf; Johannes Buchner; Birgit Strodel; Bernd Reif
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

9.  Determinants of the assembly and function of antibody variable domains.

Authors:  Eva Maria Herold; Christine John; Benedikt Weber; Stephan Kremser; Jonathan Eras; Carolin Berner; Sabrina Deubler; Martin Zacharias; Johannes Buchner
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

10.  Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab.

Authors:  Mercè Farràs; Ramón Román; Marc Camps; Joan Miret; Óscar Martínez; Xavier Pujol; Antoni Casablancas; Jordi Joan Cairó
Journal:  BMC Mol Cell Biol       Date:  2020-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.